These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Novel treatment options must prove their effectiveness: targeted treatment and immunotherapy for locally advanced melanoma]. van Thienen JV Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040280 [TBL] [Abstract][Full Text] [Related]
5. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Lo JA; Fisher DE Science; 2014 Nov; 346(6212):945-9. PubMed ID: 25414302 [TBL] [Abstract][Full Text] [Related]
6. New therapies in the treatment of melanoma. Davar D; Kirkwood JM Expert Opin Investig Drugs; 2012 Nov; 21(11):1643-59. PubMed ID: 22876817 [TBL] [Abstract][Full Text] [Related]
8. Current Clinical Trials in the Treatment of Advanced Melanomas. Sarkisian S; Nair S; Sharma R Surg Clin North Am; 2020 Feb; 100(1):201-208. PubMed ID: 31753113 [TBL] [Abstract][Full Text] [Related]
9. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411 [TBL] [Abstract][Full Text] [Related]
10. Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Basile D; Lisanti C; Pizzichetta MA; Baldo P; Fornasier G; Lo Re F; Corona G; Puglisi F Recent Pat Anticancer Drug Discov; 2019; 14(3):203-225. PubMed ID: 31362664 [TBL] [Abstract][Full Text] [Related]
11. Current and emerging systemic therapies for cutaneous metastatic melanoma. Mason R; Au L; Ingles Garces A; Larkin J Expert Opin Pharmacother; 2019 Jun; 20(9):1135-1152. PubMed ID: 31025594 [TBL] [Abstract][Full Text] [Related]
12. [Melanoma update]. Longvert C; Saiag P Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396 [TBL] [Abstract][Full Text] [Related]
13. Emerging clinical issues in melanoma in the molecularly targeted era. Sullivan RJ; Atkins MB Methods Mol Biol; 2014; 1102():11-26. PubMed ID: 24258971 [TBL] [Abstract][Full Text] [Related]
14. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Girotti MR; Saturno G; Lorigan P; Marais R Mol Oncol; 2014 Sep; 8(6):1140-58. PubMed ID: 25178978 [TBL] [Abstract][Full Text] [Related]
15. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Swe T; Kim KB Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Treatments for Advanced Resectable Melanoma. Liu JY; Lowe M J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079 [TBL] [Abstract][Full Text] [Related]
17. Emerging targeted therapies for melanoma. Johnson DB; Pollack MH; Sosman JA Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822 [TBL] [Abstract][Full Text] [Related]
18. Pathways in melanoma development. Erlich TH; Fisher DE G Ital Dermatol Venereol; 2018 Feb; 153(1):68-76. PubMed ID: 29319276 [TBL] [Abstract][Full Text] [Related]
19. Is single versus combination therapy problematic in the treatment of cutaneous melanoma? Krattinger R; Ramelyte E; Dornbierer J; Dummer R Expert Rev Clin Pharmacol; 2021 Jan; 14(1):9-23. PubMed ID: 31364890 [No Abstract] [Full Text] [Related]
20. The Emerging Therapeutic Landscape of Advanced Melanoma. Henriques V; Martins T; Link W; Ferreira BI Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]